Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Brazil's agricultural research agency gets cannabis research greenlight - 27 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- 3Doggie diversity in size and shape began at least 11,000 years ago
- 4Turning into a Distributed Writer: My Composing Process
- 5Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Pick Your Top Method for starting the Morning
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- The Main 15 Applications for Efficiency and Association
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Smartwatches: Remain Associated and Dynamic
